Innovation Pharmaceuticals Inc (IPIX)

[xoc]

I just did further research on Advexin. It's initial company Introgen went bankrupt in 2009. Adam Fuerstein maintains that Advexin doesn't work and that it's executives made false promises to investors. He states the company is trying to make a comeback under the name Multivir. Multivir has an active phase 1 trial (clinical trial identifier: NCT02842125)of what is now called Ad-p53 ,in combination with Xeloda for patients with refractory liver metastasis from colorectal cancer and other solid tumors. This study started June 2016 with anticipated primary completion date July 2018. We are ahead of this drug in the race for the p53 holy grail.